← Research hub  ·  securities

CLX · Clorox $83.82 -1.18 (-1.39%) 2026-SEP-18 12:48 EST

My allocationNot heldas of 2026-SEP-03 · allocation page ↗
Research: QT · SA · STK · FA2 mentions
2026-JUL-10 · CNBC · CNBC Halftime Report (audio edition) · Positiveinsight · read ↗ · source page ↗$94.03

In short: Harrington's final trade: a dividend aristocrat with a 5% yield at 17× earnings; as petrochemicals (its biggest cost) return to pre-war pricing and supply chains normalize, "this stock should get a pop."

In plain English

Clorox is the consumer-products maker (bleach, cleaning supplies). Jenny Harrington's final-trade pick: it's a "dividend aristocrat" (a company with a long record of raising its dividend) yielding 5% at a reasonable 17× earnings. Her catalyst is costs — petrochemicals are its biggest input, and as those prices fall back toward pre-war levels and supply chains normalize, margins should improve and "this stock should get a pop."

SOD $94.03
2026-JUL-02 · John Polomny · Actionable Intelligence Alert (paid Substack) · Positiveinsight · read ↗ · source page ↗$97.40

In short: Out-of-favor staple rounding out the income basket — cheap, low-volatility shares bought for the dividend and to sell covered calls and cash-secured puts for premium in a tax-deferred account. Held for income, outside the AIA Portfolio.

In plain English

Clorox (bleach, cleaning products, Brita, Burt's Bees) is another out-of-favor staple in the options-income basket. Same mechanics: buy the cheap, low-volatility shares, collect the dividend, and repeatedly sell short-dated covered calls and cash-secured puts for premium inside a tax-deferred account. Held for income, deliberately kept outside the AIA Portfolio.

SOD $97.40

Nothing matches this filter.

Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.